Acute and lymphomatous ATL

AZT and interferon alpha have been used to treat over 80 patients with acute or lymphomatous ATL (Table 63.5).84-91 The majority of patients had acute ATL and had received prior therapy. Overall response rates ranged from 14 to 89% with CR rates of 0-53%. Higher responses may be achieved in previously untreated patients.91 Median OS remained dismal and was usually <12 months. However, it appears to be significantly increased in responders.87,90,91

These therapeutic outcomes have not exceeded those with recent chemotherapeutic regimens, but can be administered to patients with poor performance status87 and may be associated with less toxicity, the major toxicities being hematologic.

0 0

Post a comment